Breast Cancer | Unmet Need | Metastatic HR-Positive/ HER2-Negative | US/EU | 2018

Market Outlook

Despite the number of therapy options available, metastatic HR-positive/HER2-negative breast cancer remains incurable and is a major cause of mortality and morbidity in women. Additionally, a significant need exists for therapies following hormone resistance in later lines. While the introduction of targeted therapies has helped to improve patient outcomes, a number of unmet needs and treatment gaps persist. Several emerging therapies are also poised to launch in the near term, further increasing competition in a crowded market. As this competition in HR-positive/HER2-negative breast cancer intensifies, novel therapies should more effectively address existing unmet needs to distinguish themselves from their rivals.

Questions Answered

• What are the treatment drivers most likely to influence a therapy’s uptake for metastatic HR-positive/HER2-negative breast cancer?
• How do current therapies perform on key drug attributes for metastatic HR-positive/HER2-negative breast cancer?
• What are the prevailing areas of unmet need and hidden opportunities in this patient population?
• What trade-offs are surveyed medical oncologists willing to make across different key clinical attributes and price when considering hypothetical new treatment options in metastatic HR-positive/HER2-negative breast cancer?

Product Description

Unmet Need: Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, France, Germany, United Kingdom.

Primary research: Survey of 60 medical oncologists in the United States and 30 medical oncologists in Europe.

Key drugs: Ibrance, letrozole, anastrozole, Faslodex, Kisqali, Verzenio, Afinitor, and exemestane.

Key metrics:

• Stated versus derived analysis of U.S. and European physician prescribing behavior.
• Conjoint analysis with U.S. and European physicians includes market simulator.
• Assessment of current drug performance against treatment drivers and goals.
• Physician perceptions of unmet need in metastatic HR-positive HER2-negative breast cancer and related diseases/subpopulations.
• Analysis of remaining drug development opportunities.